Scar Gel Product Family Clinical Investigation
PMCF Investigation to Compare the Clinical Performance/Benefit of Dermatix With Dermatix Ultra
The purpose of this PMCF investigation is to determine whether there are differences between the two formulations (Dermatix and Dermatix Ultra) in improving keloid and hypertrophic scars clinical symptoms and in the overall scar perception (including scar appearance and treatment perception).
This PMCF investigation has been designed to address the conclusions of the latest CER [PDPROJ-4-CE-R] and the objectives. It has been chosen as an appropriate activity as it enables the collection of device-specific data on both device formulations and on the entire intended population. Moreover, the design of the PMCF investigation (single-center, parallel, open-label, two-arm, randomized controlled study) enables the direct comparison of the clinical performance/benefit between the two formulations.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
The total number of subjects will be 75 per arm (150 total). However, to allow for potential dropouts and protocol deviations, the planned enrolment will be increased by approximately 10%, yielding a total of 84 per arm (168 total).
To ensure that both treatment groups include patients with (a) scars at risk of developing hypertrophic or keloid scars (i.e., recent scars) and (b) pre-existing hypertrophic or keloid scars (i.e., older scars), a stratified randomization procedure will be used. This approach will evenly distribute the proportion of older scars and recent scars between the two groups based on the estimated prevalence of pathological scars in the overall scar population.
Descrizione
Inclusion Criteria:
- Patients aged >3 years.
- Patients with keloids and hypertrophic scars (such as those resulting from general surgical procedures, trauma wounds, and burns), i.e., older scars.
- Patients at risk of developing keloids and hypertrophic scars, i.e., recent scars.
Exclusion Criteria:
- Patients with unhealed and/or open wounds.
- Patients with allergies to any of the ingredients.
- Pregnant or breastfeeding women.
- Patients using other topical skin treatments on/around the scar area.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Recent Scar
Patients at risk of developing a hypertrophic or keloid scar, aged 3 years and older.
|
Patients will be supplied with two 15g tubes of Dermatix at Visit 1 - Baseline Visit with the clinician, which will be sufficient to last the duration of the study (6-months) when applied as instructed (i.e.
twice daily).
If for any reason the patient runs out of the investigational product, a contingency supply will be in place and patients will be supplied with an additional tube.
Patients will also be provided with the IFU of the supplied device and the clinician will provide instructions as to the application, frequency, and duration of use of the device (i.e.
applied topically to the scar, twice daily for 6 months/until final study visit).
Patients will be supplied with two 15g tubes of Dermatix Ultra at Visit 1 - Baseline Visit with the clinician, which will be sufficient to last the duration of the study (6-months) when applied as instructed (i.e.
twice daily).
If for any reason the patient runs out of the investigational product, a contingency supply will be in place and patients will be supplied with an additional tube.
Patients will also be provided with the IFU of the supplied device and the clinician will provide instructions as to the application, frequency, and duration of use of the device (i.e.
applied topically to the scar, twice daily for 6 months/until final study visit).
|
|
Older Scars
Patients with existing scars, aged 3 years and older,
|
Patients will be supplied with two 15g tubes of Dermatix at Visit 1 - Baseline Visit with the clinician, which will be sufficient to last the duration of the study (6-months) when applied as instructed (i.e.
twice daily).
If for any reason the patient runs out of the investigational product, a contingency supply will be in place and patients will be supplied with an additional tube.
Patients will also be provided with the IFU of the supplied device and the clinician will provide instructions as to the application, frequency, and duration of use of the device (i.e.
applied topically to the scar, twice daily for 6 months/until final study visit).
Patients will be supplied with two 15g tubes of Dermatix Ultra at Visit 1 - Baseline Visit with the clinician, which will be sufficient to last the duration of the study (6-months) when applied as instructed (i.e.
twice daily).
If for any reason the patient runs out of the investigational product, a contingency supply will be in place and patients will be supplied with an additional tube.
Patients will also be provided with the IFU of the supplied device and the clinician will provide instructions as to the application, frequency, and duration of use of the device (i.e.
applied topically to the scar, twice daily for 6 months/until final study visit).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Vancouver Scar Scale (VSS)
Lasso di tempo: 6 months of treatment
|
Comparison of clinical symptoms and scar appearance between Dermatix and Dermatix Ultra (between the two study arms) using the Vancouver Scar Scale (VSS), i.e.,
|
6 months of treatment
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Satisfaction, Change from Baseline, Complications
Lasso di tempo: 6 months of treatment
|
|
6 months of treatment
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- PDPROJ-4-CI-P
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Dermatix
-
University Hospital Schleswig-HolsteinSconosciutoCicatrice, ipertrofica | CheloideGermania
-
Innovative MedicalCompletato
-
Chang Gung Memorial HospitalCompletato
-
Chang Gung Memorial HospitalSconosciuto
-
Samsung Medical CenterSeoul National University Hospital; Kyunghee University Medical Center; InovailSconosciutoCicatrice ipertroficaCorea, Repubblica di
-
Mahidol UniversityCompletatoCicatrici ipertrofiche | CheloidiTailandia
-
University Hospital, GhentCompletatoTessuto cicatriziale o pelle sanaBelgio